克罗恩病生物制剂治疗一年临床结局:透壁愈合与黏膜愈合或无愈合的比较
前瞻性纵向观察研究纳入完成2年抗TNFα治疗的218例克罗恩病患者,用肠道超声判定透壁愈合(肠壁厚度≤3 mm)。68例(31.2%)达透壁(合并黏膜)愈合,60例(27.5%)仅黏膜愈合,90例(41.3%)未达任何肠道愈合。透壁愈合者1年无激素临床缓解率更高、住院率与手术需求更低,且停药后结局仍优于黏膜愈合。
要点
- 透壁愈合者1年无激素临床缓解率为95.6%,高于仅黏膜愈合的75%和无愈合的41%(P < 0.001)。
- 透壁愈合者1年住院率为8.8%、手术需求为0%,均低于仅黏膜愈合(28.3%、10%)和无愈合(66.6%、35.5%)(P < 0.001)。
- 透壁愈合较黏膜愈合的临床复发(HR 0.87,P = 0.01)、住院(HR 0.88,P = 0.002)和手术(HR 0.94,P = 0.008)时间间隔更长。
核心结论
- 透壁愈合是更高要求且有力的治疗目标,较黏膜愈合在更大程度上与全部临床结局的改善相关。
- 停用生物制剂后,透壁愈合仍与优于黏膜愈合的长期临床结局相关。
研究设计与样本
- 观察性纵向研究,评估接受抗TNFα治疗2年的克罗恩病患者1年结局(无激素临床缓解、住院率、手术需求)。
- 共218例完成2年抗TNFα疗程,全部患者用肠道超声判定透壁愈合。
主要发现
- 218例中68例(31.2%)达透壁(合并黏膜)愈合(肠道超声示肠壁厚度≤3 mm),60例(27.5%)仅黏膜愈合,90例(41.3%)未达任何肠道愈合。
- 1年无激素临床缓解率:透壁愈合95.6% vs 仅黏膜愈合75% vs 无愈合41%(P < 0.001)。
- 1年住院率:透壁愈合8.8% vs 仅黏膜愈合28.3% vs 无愈合66.6%(P < 0.001)。
- 1年手术需求:透壁愈合0% vs 仅黏膜愈合10% vs 无愈合35.5%(P < 0.001)。
- 透壁愈合较黏膜愈合至临床复发(HR 0.87,P = 0.01)、住院(HR 0.88,P = 0.002)、手术(HR 0.94,P = 0.008)的间隔更长。
关键数值与推荐
- 透壁愈合判定标准:肠道超声示肠壁厚度≤3 mm。
- 在停用生物制剂的患者中,透壁愈合预测1年临床结局优于黏膜愈合(P = 0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While mucosal healing has been proved to predict relevant clinical outcomes in Crohn's disease (CD), little is known about the long-term significance of transmural healing. AIMS: To prospectively assess the 1-year clinical outcomes in CD patients achieving transmural healing following treatment with biologics, and to compare them with those in patients reaching only mucosal healing or no healing. METHODS: Observational longitudinal study, evaluating 1-year outcomes in terms of steroid-free clinical remission, rate of hospitalisation and need for surgery in a group of CD patients treated with anti-tumour necrosis factor (TNF) alpha for 2 years. Bowel sonography was used in all patients to determine transmural healing. RESULTS: Of 218 patients who completed a 2-year treatment course with anti-TNF alpha, 68 (31.2%) presented transmural (plus mucosal) healing (bowel wall thickness ≤3 mm at bowel sonography), 60 (27.5%) mucosal healing only, and 90 (41.3%) did not achieve any intestinal healing. Transmural healing was associated with a higher rate of steroid-free clinical remission (95.6%), lower rates of hospitalisation (8.8%) and need for surgery (0%) at 1 year compared to mucosal (75%, 28.3% and 10%, respectively) and no healing (41%, 66.6% and 35.5%, respectively) (P < 0.001). Furthermore, transmural healing was associated with longer intervals until clinical relapse (HR, hazard ratio 0.87, P = 0.01), hospitalisation (HR 0.88, P = 0.002) and surgery (HR 0.94, P = 0.008) than mucosal healing. Also among patients discontinuing treatment with biologics, transmural healing predicted better clinical outcomes at 1 year than mucosal healing (P = 0.01). CONCLUSIONS: Transmural healing is an ambitious and powerful treatment goal associated, to a greater extent than mucosal healing, with improvement of all clinical outcomes. Additionally, transmural healing is associated with better long-term clinical outcomes than mucosal healing also after discontinuation of biologics.
引用
- Castiglione F, Imperatore N, Testa A, et al. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther. 2019. PMID: 30854708. doi:10.1111/apt.15190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。